Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Sutent

- PMLiVE

Pfizer and Flagship Pioneering enter autoimmune disease partnership

More than 100 known types of autoimmune diseases affect over 50 million people in the US

- PMLiVE

Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years

Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group

- PMLiVE

Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study

It is estimated that nearly 320,000 people will be diagnosed with the disease in the US this year

- PMLiVE

Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

Approximately 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma

Up to 70% of patients with this form of non-Hodgkin lymphoma are diagnosed with advanced disease

- PMLiVE

Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer

An estimated 154,270 people will be diagnosed with cancer of the colon or rectum in the US this year

- PMLiVE

Pfizer shares positive late-stage results for Braftovi regimen in colorectal cancer

The combination was approved in the US last month to treat BRAF V600E-mutant disease

- PMLiVE

Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer in the UK every year

- PMLiVE

Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer

The disease is the third most common type of cancer globally

- PMLiVE

Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

The genetic blood disorder affects more than 800,000 people globally

- PMLiVE

Pfizer appoints Chris Boshoff as chief scientific officer and president of R&D

Boshoff has most recently been serving as the company’s chief oncology officer and executive vice president

- PMLiVE

Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma

Approximately 5,000 people are diagnosed with the disease every year in England

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links